JP2023159112A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023159112A5 JP2023159112A5 JP2023123893A JP2023123893A JP2023159112A5 JP 2023159112 A5 JP2023159112 A5 JP 2023159112A5 JP 2023123893 A JP2023123893 A JP 2023123893A JP 2023123893 A JP2023123893 A JP 2023123893A JP 2023159112 A5 JP2023159112 A5 JP 2023159112A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- acid sequence
- amino acid
- chain
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 119
- 229920001184 polypeptide Polymers 0.000 claims 55
- 108090000765 processed proteins & peptides Proteins 0.000 claims 55
- 102000004196 processed proteins & peptides Human genes 0.000 claims 55
- 150000001413 amino acids Chemical class 0.000 claims 48
- 108091008874 T cell receptors Proteins 0.000 claims 17
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 17
- 102000004169 proteins and genes Human genes 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 5
- 239000013604 expression vector Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 238000003259 recombinant expression Methods 0.000 claims 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024178808A JP7814467B2 (ja) | 2017-09-29 | 2024-10-11 | 変異型ｐ５３を認識するｔ細胞受容体 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762565383P | 2017-09-29 | 2017-09-29 | |
| US62/565,383 | 2017-09-29 | ||
| JP2020517556A JP7324193B2 (ja) | 2017-09-29 | 2018-09-17 | 変異型ｐ５３を認識するｔ細胞受容体 |
| PCT/US2018/051285 WO2019067243A1 (en) | 2017-09-29 | 2018-09-17 | T CELL RECEPTORS RECOGNIZING P53 MUTE |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517556A Division JP7324193B2 (ja) | 2017-09-29 | 2018-09-17 | 変異型ｐ５３を認識するｔ細胞受容体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024178808A Division JP7814467B2 (ja) | 2017-09-29 | 2024-10-11 | 変異型ｐ５３を認識するｔ細胞受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023159112A JP2023159112A (ja) | 2023-10-31 |
| JP2023159112A5 true JP2023159112A5 (https=) | 2023-11-29 |
| JP7573075B2 JP7573075B2 (ja) | 2024-10-24 |
Family
ID=63714167
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517556A Active JP7324193B2 (ja) | 2017-09-29 | 2018-09-17 | 変異型ｐ５３を認識するｔ細胞受容体 |
| JP2023123893A Active JP7573075B2 (ja) | 2017-09-29 | 2023-07-28 | 変異型ｐ５３を認識するｔ細胞受容体 |
| JP2024178808A Active JP7814467B2 (ja) | 2017-09-29 | 2024-10-11 | 変異型ｐ５３を認識するｔ細胞受容体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517556A Active JP7324193B2 (ja) | 2017-09-29 | 2018-09-17 | 変異型ｐ５３を認識するｔ細胞受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024178808A Active JP7814467B2 (ja) | 2017-09-29 | 2024-10-11 | 変異型ｐ５３を認識するｔ細胞受容体 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11939365B2 (https=) |
| EP (2) | EP4647442A3 (https=) |
| JP (3) | JP7324193B2 (https=) |
| KR (2) | KR20250024096A (https=) |
| CN (2) | CN111386282B (https=) |
| AU (2) | AU2018342246B2 (https=) |
| BR (1) | BR112020006012A2 (https=) |
| CA (1) | CA3077024A1 (https=) |
| CR (4) | CR20240303A (https=) |
| DK (1) | DK3688027T3 (https=) |
| EA (1) | EA202090757A1 (https=) |
| ES (1) | ES3056082T3 (https=) |
| FI (1) | FI3688027T3 (https=) |
| IL (1) | IL273515B2 (https=) |
| MA (1) | MA50651A (https=) |
| MX (4) | MX421596B (https=) |
| PL (1) | PL3688027T3 (https=) |
| PT (1) | PT3688027T (https=) |
| SG (1) | SG11202002636PA (https=) |
| WO (1) | WO2019067243A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE058957T2 (hu) | 2016-12-08 | 2022-10-28 | Immatics Biotechnologies Gmbh | Új T-sejt receptorok és velük végzett immunterápia |
| CA3080274A1 (en) * | 2017-09-29 | 2019-04-04 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation |
| WO2020237368A1 (en) * | 2019-05-27 | 2020-12-03 | Provincial Health Services Authority | Immunotherapy constructs targeting kras antigens |
| CA3144070A1 (en) * | 2019-06-27 | 2020-12-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing r175h or y220c mutation in p53 |
| CN113512124A (zh) * | 2020-04-10 | 2021-10-19 | 香雪生命科学技术（广东）有限公司 | 一种识别hpv16的高亲和力tcr |
| EP4208473A2 (en) * | 2020-09-04 | 2023-07-12 | The United States of America, as represented by the Secretary, Department of Health and Human Services | T cell receptors recognizing r273c or y220c mutations in p53 |
| IL305393A (en) | 2021-02-25 | 2023-10-01 | Alaunos Therapeutics Inc | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| WO2022236050A1 (en) * | 2021-05-07 | 2022-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing c135y, r175h, or m237i mutation in p53 |
| WO2023050063A1 (zh) * | 2021-09-28 | 2023-04-06 | 溧阳瑅赛生物医药有限公司 | 一种识别hla-a*02:01/e629-38的tcr及其应用 |
| EP4423143A4 (en) * | 2021-10-29 | 2025-10-01 | Yafei Hou | T CELL RECEPTOR RECOGNIZING R175H MUTATION IN P53 AND ITS APPLICATION |
| US20250145950A1 (en) | 2022-02-01 | 2025-05-08 | Alaunos Therapeutics, Inc. | Methods for Activation and Expansion of T Cells |
| US20240035027A1 (en) * | 2022-05-04 | 2024-02-01 | University Of Massachusetts | Oligonucleotides for pms2 modulation |
| CN116063577B (zh) * | 2022-11-18 | 2025-02-07 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| WO2024206274A2 (en) | 2023-03-27 | 2024-10-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting y220c or r175h mutation in p53 |
| WO2025024648A2 (en) * | 2023-07-25 | 2025-01-30 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting tp53 hotspot mutations and uses thereof |
| WO2025060149A1 (zh) * | 2023-09-22 | 2025-03-27 | 上海市第一人民医院 | 一种分离的tcr及其用途 |
| WO2025226769A1 (en) * | 2024-04-24 | 2025-10-30 | Bluesphere Bio, Inc. | T cell receptors targeting minor histocompatibility antigen lrh-1 |
| WO2025250587A1 (en) | 2024-05-29 | 2025-12-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Drug-regulatable, inducible cytokine expression |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6770749B2 (en) * | 2000-02-22 | 2004-08-03 | City Of Hope | P53-specific T cell receptor for adoptive immunotherapy |
| AU2002316190B8 (en) * | 2001-06-05 | 2009-01-29 | Altor Bioscience Corporation | p53 binding T cell receptor molecules and uses thereof |
| AU2003265948B8 (en) | 2002-09-06 | 2009-09-03 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| RU2721423C2 (ru) | 2013-08-07 | 2020-05-19 | Йеда Ресеарч Энд Девелопмент Ко. Лтд. | Пептиды, способные реактивировать мутанты р53 |
| EP3656864A1 (en) * | 2014-02-14 | 2020-05-27 | Board of Regents, The University of Texas System | Chimeric antigen receptors and methods of making |
| KR20160145802A (ko) * | 2014-04-23 | 2016-12-20 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법 |
| IL290655B2 (en) | 2014-05-29 | 2024-05-01 | Us Health | Anti-human papillomavirus 16 E7 T-cell chelates |
| US10973894B2 (en) | 2014-10-02 | 2021-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Methods of isolating T cells having antigenic specificity for a cancer-specific mutation |
| AU2014407539B2 (en) * | 2014-10-02 | 2020-10-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation |
| WO2016141169A1 (en) | 2015-03-03 | 2016-09-09 | Caris Mpi, Inc. | Molecular profiling for cancer |
| US10544392B2 (en) * | 2015-05-01 | 2020-01-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
| TW202523682A (zh) | 2015-05-20 | 2025-06-16 | 美商博德研究所有限公司 | 共有之gata3相關之腫瘤特異性新抗原 |
| US11047011B2 (en) * | 2015-09-29 | 2021-06-29 | iRepertoire, Inc. | Immunorepertoire normality assessment method and its use |
-
2018
- 2018-09-17 EA EA202090757A patent/EA202090757A1/ru unknown
- 2018-09-17 EP EP25200391.8A patent/EP4647442A3/en active Pending
- 2018-09-17 CN CN201880074539.8A patent/CN111386282B/zh active Active
- 2018-09-17 CR CR20240303A patent/CR20240303A/es unknown
- 2018-09-17 CA CA3077024A patent/CA3077024A1/en active Pending
- 2018-09-17 FI FIEP18780006.5T patent/FI3688027T3/fi active
- 2018-09-17 KR KR1020257002917A patent/KR20250024096A/ko active Pending
- 2018-09-17 PT PT187800065T patent/PT3688027T/pt unknown
- 2018-09-17 JP JP2020517556A patent/JP7324193B2/ja active Active
- 2018-09-17 PL PL18780006.5T patent/PL3688027T3/pl unknown
- 2018-09-17 MX MX2020003504A patent/MX421596B/es unknown
- 2018-09-17 AU AU2018342246A patent/AU2018342246B2/en active Active
- 2018-09-17 IL IL273515A patent/IL273515B2/en unknown
- 2018-09-17 MA MA050651A patent/MA50651A/fr unknown
- 2018-09-17 EP EP18780006.5A patent/EP3688027B1/en active Active
- 2018-09-17 WO PCT/US2018/051285 patent/WO2019067243A1/en not_active Ceased
- 2018-09-17 BR BR112020006012-7A patent/BR112020006012A2/pt unknown
- 2018-09-17 CR CR20240302A patent/CR20240302A/es unknown
- 2018-09-17 US US16/651,242 patent/US11939365B2/en active Active
- 2018-09-17 SG SG11202002636PA patent/SG11202002636PA/en unknown
- 2018-09-17 CN CN202411117183.5A patent/CN118955684A/zh active Pending
- 2018-09-17 CR CR20250153A patent/CR20250153A/es unknown
- 2018-09-17 ES ES18780006T patent/ES3056082T3/es active Active
- 2018-09-17 KR KR1020207012344A patent/KR102762272B1/ko active Active
- 2018-09-17 CR CR20200170A patent/CR20200170A/es unknown
- 2018-09-17 DK DK18780006.5T patent/DK3688027T3/da active
-
2020
- 2020-07-13 MX MX2024005678A patent/MX2024005678A/es unknown
- 2020-07-13 MX MX2024005677A patent/MX2024005677A/es unknown
- 2020-07-13 MX MX2024005676A patent/MX2024005676A/es unknown
-
2023
- 2023-07-28 JP JP2023123893A patent/JP7573075B2/ja active Active
-
2024
- 2024-02-21 US US18/583,139 patent/US20240270814A1/en active Pending
- 2024-10-11 JP JP2024178808A patent/JP7814467B2/ja active Active
- 2024-10-28 AU AU2024227695A patent/AU2024227695A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023159112A5 (https=) | ||
| JP2017536825A5 (https=) | ||
| JP2018535647A5 (https=) | ||
| Ho et al. | Bacteriophage λ protein c II binds promoters on the opposite face of the DNA helix from RNA polymerase | |
| FI3688027T3 (fi) | Mutatoidun p53:n tunnistavia t-solureseptoreita | |
| CN112851804B (zh) | 一种人源抗新型冠状病毒(SARS-CoV-2)的中和活性单克隆抗体 | |
| JP2020511936A5 (https=) | ||
| WO2024109611A1 (zh) | 突变型呼吸道合胞病毒融合前f蛋白及其应用 | |
| CN111778218A (zh) | 噬菌体展示抗体库及基于其淘筛获得的针对新冠病毒SARS-CoV-2的单克隆抗体 | |
| JP2021500010A5 (https=) | ||
| JP2014500002A5 (https=) | ||
| JP2020534828A5 (https=) | ||
| JP6907229B2 (ja) | ヒト化抗ｃｌｅｖｅｒ−１抗体およびその使用 | |
| DK2688907T3 (en) | DOMINANT NEGATIVE HSP110 MUTANT AND ITS APPLICATION TO FORECAST AND treatment of cancers | |
| JP2016503295A5 (https=) | ||
| JP2015525208A5 (https=) | ||
| JP2015506945A5 (https=) | ||
| JP2007506417A5 (https=) | ||
| Li et al. | Nanobody against the E7 oncoprotein of human papillomavirus 16 | |
| CN115335400A (zh) | 结合整合素avb8的抗体及其用途 | |
| WO2025246679A1 (zh) | 一种广谱中和冠状病毒的抗体及其应用 | |
| CA3205854A1 (en) | Therapeutic and diagnostic agents and uses thereof | |
| CN111378048A (zh) | 针对中东呼吸综合征冠状病毒的抗体-多肽双特异性免疫治疗剂 | |
| Iizuka et al. | APOBEC 3G is increasingly expressed on the human uterine cervical intraepithelial neoplasia along with disease progression | |
| CN118652334A (zh) | 一种靶向钙粘蛋白17的纳米抗体及其应用 |